KCT0002467
Recruiting
未知
EUS guided RFA for the management of pancreatic and peripancreatic tumor; efficacy and safety evaluation
ConditionsDiseases of the digestive system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the digestive system
- Sponsor
- Asan Medical Center
- Enrollment
- 25
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Persons who are able to understand clinical trials of Adults under the age of 20 and under 80 years old who are voluntarily agreed to participate in this clinical trial, voluntarily agreeing to sign consent for this clinical trial.
- •2\. Patients who have been diagnosed with tumors of pancreas and pancreatic tumors using biopsy.
- •3\. Estimated expectation period of 6 months or more.
- •4\. Patients who are inoperable and can not be Received radiation therapy due to a lack of immunity.
- •5\. Patients who do not respond to existing anti\-cancer drugs and radiation therapy
- •6\. cancer patient is examined by CT or MRI
- •7\. Patients with \= 50 % of Karnofsky performance status
- •8\. Patient whose results are normal in the blood coagulation test
- •9\. Female of child bearing age must have negative results in pregnancy examinations..
- •10\. Patients who follow the clinical trial procedure and comply with the visit schedule.
Exclusion Criteria
- •1\. Patient who can not see images of endoscopic ultrasonography.
- •2\. Patients with an obstruction in the endoscopy path
- •3\. disseminated intravascular coagulation
- •4\. Patients who are taking drugs that can cause bleeding, such as aspirin..
- •5\. Chronic obstructive or restrictive chronic lung disease, including breathing difficulty during recess
- •6\. Other serious diseases or medical conditions.
- •7\. Pregnant women, breastfeeding women, and women of child bearing age who don't use proper contraception.
- •8\. Other medical condition that may impair the ability of patients to participate in clinical trials.
- •9\. Patients with significant neurologic or psychiatric disorder, such as dementia or strokes.
- •10\. Despite the treatment unstable heart disease, a heart attack occurs within six months prior to the clinical trial (Even if a heart attack is diagnosed within six months prior to the clinical trial, a heart condition that remains stable is possible for enroll the study.)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The feasibility and efficacy of EUS-guided pancreatic duct drainage using the novel pancreatic duct stentJPRN-UMIN000012447Department of the 4th Internal medicine, Tokyo Medical University Hospital20
Completed
Not Applicable
Fine-needle aspiration guided by endoscopic ultrasonography (EUS FNA) in pancreatic massesISRCTN69545565Geneva University Hospital (Switzerland)45
Completed
Not Applicable
Effectiveness and sfety of EUS-guided pancreatic duct drainageJPRN-UMIN000015326Okayama University Hospital10
Completed
Phase 2
EUS-FNA for pancreato-biliary cancers as preoperative study method to evaluate paraaortic lymph node metastasis.pancreatic cancer, biliary tract cancerJPRN-UMIN000006408Department of gastroenterology ahd hepatology, Kyoto University50
Recruiting
Not Applicable
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine TumorsNeuroendocrine Tumor of Pancreas (Disorder)Neuroendocrine Tumor Grade 1NCT04520932Institut Paoli-Calmettes82